MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

Rhea-AI Summary

MediWound (Nasdaq: MDWD) reported fourth-quarter and full-year 2025 results on March 5, 2026. Full-year revenue was $17.0 million and year-end cash totaled $53.6 million. The expanded NexoBrid manufacturing facility is operational, and EscharEx Phase III VALUE trial enrollment and interim assessment are expected by year-end 2026.

The company reaffirmed 2026–2028 revenue guidance of $24–26M, $32–35M and $50–55M respectively; regulatory approvals for expanded supply are expected in 2026.

Positive

• Cash balance of $53.6 million at December 31, 2025
• Expanded NexoBrid facility operational with 6x production capacity
• Reaffirmed revenue guidance: $24–26M (2026), $32–35M (2027), $50–55M (2028)
• EscharEx Phase III VALUE trial progressing; interim assessment and enrollment completion expected by year-end 2026
• Net loss improved to $23.9M in 2025 from $30.2M in 2024

Negative

• Full-year revenue declined to $17.0 million from $20.2M in 2024 (≈15.8% decrease)
• R&D spend rose to $14.3 million in 2025 from $8.9M in 2024 (≈61% increase)
• Operating loss widened to $25.3 million in 2025 from $19.4M in 2024

News Market Reaction – MDWD

-0.85%

1 alert

-0.85% News Effect

On the day this news was published, MDWD declined 0.85%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

2025 Revenue: $17.0 million Q4 2025 Revenue: $1.9 million Year-end Cash: $53.6 million +5 more

8 metrics

2025 Revenue $17.0 million Full year 2025 vs $20.2 million in 2024

Q4 2025 Revenue $1.9 million Quarter vs $5.8 million in Q4 2024

Year-end Cash $53.6 million Cash, equivalents and deposits as of Dec 31, 2025

2025 Net Loss $23.9 million Full year 2025, EPS $2.10 loss

Q4 2025 Net Loss $7.2 million Quarterly loss, EPS $0.56 loss

2025 Adj. EBITDA Loss $20.3 million Non-GAAP Adjusted EBITDA for 2025

2026 Revenue Guidance $24–26 million Reaffirmed outlook for 2026

VALUE Trial Size 216 patients Global Phase III EscharEx VALUE study in VLUs

Market Reality Check

Price: $17.49 Vol: Volume 74,776 is slightly...

normal vol

$17.49 Last Close

Volume Volume 74,776 is slightly below the 20-day average of 84,422 (relative volume 0.89). normal

Technical Shares trade below the 200-day MA of 18.54 at a pre-news level of 17.60, about mid-range between 52-week low 14.14 and high 22.51.

Peers on Argus

Biotech peers are mixed: core comparables show both gains and losses, while mome...

2 Up

Biotech peers are mixed: core comparables show both gains and losses, while momentum scanners flagged HUMA and TNYA modestly up. With MDWD up 2.33% pre-release and limited aligned peer strength, moves appear more company-specific than sector-driven.

Previous Earnings Reports

5 past events · Latest: Nov 20 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 20	Q3 2025 earnings	Positive	-5.6%	Reported Q3 2025 growth, facility commissioning, and EscharEx trial progress.
Aug 14	Q2 2025 earnings	Positive	-1.0%	Q2 2025 revenue growth, NexoBrid momentum, new funding and partnerships.
May 21	Q1 2025 earnings	Positive	-4.7%	Q1 2025 results with VALUE trial updates and NexoBrid demand growth.
Mar 19	FY 2024 results	Positive	-5.1%	Full-year 2024 growth, VALUE trial initiation, and funding milestones.
Nov 26	Q3 2024 earnings	Positive	-2.5%	Q3 2024 results with NexoBrid approval and financing updates.

Pattern Detected

Earnings and financial updates have typically been received negatively, with all five recent earnings-related releases showing share price declines despite generally constructive operational commentary.

Recent Company History

Over the past five quarters, MediWound’s news flow has focused on recurring earnings updates and steady development of EscharEx’s VALUE Phase III program and NexoBrid capacity. Earnings releases on Mar 19, 2024, and throughout 2025 highlighted revenue growth phases, expanded partnerships, and significant financings, yet the stock often traded lower afterward. Today’s full-year 2025 results and reaffirmed 2026–2028 guidance extend that narrative of clinical and manufacturing execution paired with ongoing operating losses.

Historical Comparison

-3.8% avg move · In the last 5 earnings releases, MDWD’s average move was -3.78%, even as updates highlighted VALUE P...

earnings

-3.8%

Average Historical Move earnings

In the last 5 earnings releases, MDWD’s average move was -3.78%, even as updates highlighted VALUE Phase III progress and NexoBrid capacity expansion.

Earnings reports from late 2024 through 2025 show a consistent pattern: quarterly and annual results paired with advancing EscharEx VALUE Phase III, expanding NexoBrid manufacturing sixfold, and periodic financings to support development and commercialization plans.

Market Pulse Summary

This announcement details MediWound’s 2025 results, including $17.0 million in revenue, a $23.9 mill...

Analysis

This announcement details MediWound’s 2025 results, including $17.0 million in revenue, a $23.9 million net loss, and year-end cash of $53.6 million, alongside reaffirmed revenue guidance through 2028. Key themes are heavier R&D spending on the EscharEx VALUE Phase III trial, an operational NexoBrid facility, and multi-indication expansion plans. Investors may watch upcoming VALUE milestones, NexoBrid regulatory approvals expected in 2026, and whether revenue tracks within the $24–26 million 2026 range.

Key Terms

phase iii, phase ii, venous leg ulcers, diabetic foot ulcers, +4 more

8 terms

phase iii medical

"Our Phase III VALUE trial of EscharEx continues to progress as planned"

A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.

phase ii medical

"A Phase II study in diabetic foot ulcers (DFUs) and an investigator-initiated trial"

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

venous leg ulcers medical

"global Phase III VALUE study in venous leg ulcers (VLUs), targeting 216 patients"

A venous leg ulcer is an open sore on the lower leg that develops when veins fail to return blood effectively, causing long-term swelling and skin breakdown—think of it as a persistent pothole where poor drainage keeps making the surface worse. Investors track these wounds because they create sustained demand for treatments, dressings, devices and home-care services, affect healthcare spending and reimbursement patterns, and can drive sales and regulatory interest in new therapies.

diabetic foot ulcers medical

"A Phase II study in diabetic foot ulcers (DFUs) and an investigator-initiated trial"

A diabetic foot ulcer is an open sore or wound on the foot that occurs when high blood sugar and nerve damage prevent normal healing, much like a small pothole that keeps widening because the road can’t be properly repaired. It matters to investors because these wounds drive demand for treatments, medical devices, wound-care drugs and hospital services, and they carry risks of infection and amputation that can shape healthcare costs, reimbursement decisions and clinical trial opportunities.

pressure ulcers medical

"and an investigator-initiated trial (IIT) in pressure ulcers (PUs) are planned"

Pressure ulcers are areas of skin and underlying tissue damage that develop when constant pressure or friction cuts off blood flow, like a bruise that gets worse when a spot is pressed for too long. Investors track them because they signal care quality, drive treatment and legal costs, affect hospital and nursing-home ratings, and influence reimbursement and regulatory scrutiny—factors that can change a health provider’s revenue and reputation.

adjusted ebitda financial

"Non-GAAP Adjusted EBITDA loss was $20.3 million, compared to a loss"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

ifrs financial

"consolidated financial statements prepared and presented in accordance with IFRS"

International Financial Reporting Standards (IFRS) are a set of common accounting rules used by many companies worldwide to prepare financial statements, so numbers like revenue, profit and assets are measured in the same way across borders. For investors, IFRS matters because it makes it easier to compare the financial health and performance of different companies—like using the same ruler to measure different objects—reducing surprises and helping informed investment decisions.

registered direct offering financial

"through a $30.0 million registered direct offering and $3.5 million in proceeds"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

AI-generated analysis. Not financial advice.

EscharEx^® Phase III VALUE trial advancing as planned

Expanded NexoBrid^® manufacturing facility operational; regulatory approvals expected in 2026

$17 million revenue in 2025; $54 million in cash at year-end; 2026–2028 revenue guidance reaffirmed

Conference Call Today, March 5, 2026, at 8:30 a.m. Eastern Time

YAVNE, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2025.

“We entered 2026 with two strategic growth drivers,” said Ofer Gonen, Chief Executive Officer of MediWound. “Our Phase III VALUE trial of EscharEx continues to progress as planned, with key clinical milestones, including interim assessment and enrollment completion, anticipated by year-end. In parallel, our expanded NexoBrid manufacturing facility is now operational, positioning us to support global demand following regulatory approvals. With these value-creating catalysts, a strong balance sheet, and an experienced team, MediWound is now well-positioned to advance into a new phase of scale and commercial readiness.”

Fourth Quarter 2025 Highlights, Recent Developments, and Upcoming Milestones

EscharEx^®

• Enrollment continues in the global Phase III VALUE study in venous leg ulcers (VLUs), targeting 216 patients across approximately 40 sites in the U.S. and Europe, the majority of which are active and enrolling patients. The pre-specified interim sample size assessment and enrollment completion are expected by year-end 2026.
• The EscharEx clinical program is expanding into two additional indications. A Phase II study in diabetic foot ulcers (DFUs) and an investigator-initiated trial (IIT) in pressure ulcers (PUs) are planned for the second half of 2026.
• B. Braun joined the EscharEx clinical development program through a research collaboration agreement, alongside existing collaborations with Coloplast/Kerecis, Convatec, Essity, Mölnlycke, Solventum, and MIMEDX.
  

NexoBrid^®

• U.S. adoption continues to expand, with Vericel reporting broad utilization across more than 70 burn centers, representing the majority of its approximately 90 target accounts.
• The expanded NexoBrid manufacturing facility is now operational, increasing production capacity sixfold to support anticipated global demand. Commercial supply from the facility remains subject to regulatory approvals expected in 2026.

Fourth Quarter 2025 Financial Highlights

• Revenue for the fourth quarter was $1.9 million, compared to $5.8 million in the fourth quarter of 2024. The decrease was primarily due to lower development services revenue, mainly attributable to the U.S. government shutdown, which delayed budget approvals and the initiation of new contractual agreements.
• Gross profit was $0.3 million, representing a gross margin of 14.9%, compared to $0.9 million and a gross margin of 15.5% in the fourth quarter of 2024.
• Research and development expenses were $4.5 million, compared to $3.0 million in the fourth quarter of 2024, primarily due to costs associated with the EscharEx VALUE Phase III trial.
• Selling, general and administrative expenses totaled $3.6 million, compared to $4.0 million in the prior-year quarter, mainly reflecting a decrease in marketing and share-based compensation expenses.
• Operating loss was $7.8 million, compared to $6.1 million in the fourth quarter of 2024.
• Net loss was $7.2 million, or $0.56 per share, compared to a net loss of $3.9 million, or $0.36 per share, in the fourth quarter of 2024. The increase was primarily attributable to lower non-cash financial income from the revaluation of warrants.
• Non-GAAP Adjusted EBITDA loss was $6.5 million, compared to a loss of $4.9 million in the same period last year.
  

Full Year 2025 Financial Highlights

• Revenue for 2025 totaled $17.0 million, compared to $20.2 million in 2024. The decrease was primarily attributable to the U.S. government shutdown, which delayed budget approvals and the initiation of new contractual agreements, as well as lower product sales to Vericel.
• Gross profit for the year was $3.3 million, representing a gross margin of 19.2%, compared to $2.6 million and a gross margin of 13.0% in 2024. The increase primarily reflects a favorable change in revenue mix.
• Research and development expenses increased to $14.3 million from $8.9 million in 2024, primarily due to costs associated with the EscharEx VALUE Phase III trial.
• Selling, general and administrative expenses were $14.2 million, compared to $13.1 million in 2024, mainly reflecting higher Marketing Authorization Holder (MAH) expenses.
• Operating loss was $25.3 million, compared to $19.4 million in 2024.
• Net loss for 2025 was $23.9 million, or $2.10 per share, compared to $30.2 million, or $3.03 per share, in 2024. The reduction in net loss was primarily driven by $2.2 million of non-cash financial income from the revaluation of warrants in 2025, compared to $10.7 million of non-cash financial expense from the revaluation of warrants in 2024.
• Non-GAAP Adjusted EBITDA loss was $20.3 million, compared to a loss of $14.8 million in 2024.
  

2026–2028 Outlook

• The Company reaffirms its revenue guidance of $24–26 million for 2026, $32–35 million for 2027, and $50–55 million for 2028. Guidance assumes continued support from BARDA and the U.S. Department of War. The 2028 outlook includes a potential initial contribution from EscharEx, subject to regulatory approval.
  

Balance Sheet Highlights

• As of December 31, 2025, cash, cash equivalents and deposits totaled $53.6 million, compared to $43.6 million as of December 31, 2024.
• During 2025, the Company used $21.4 million in cash to fund operating activities.
• In 2025, the Company strengthened its balance sheet through a $30.0 million registered direct offering and $3.5 million in proceeds from Series A warrant exercises.
  

Conference Call and Webcast

MediWound management will host a conference call for investors on Thursday, March 5, 2026, beginning at 8:30 a.m., Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may join the conference call by dialing 1-844-676-8833 (in the U.S.), 1-80-921-2373 (Israel), or 1-412-634-6869 (outside the U.S. & Israel). The call will be available via webcast by clicking HERE or on the Events & Presentations page of the Company’s website.

A replay of the call will be available on the Company’s website at www.mediwound.com.

Non-IFRS Financial Measures

To supplement consolidated financial statements prepared and presented in accordance with IFRS, the Company has provided a supplementary non-IFRS measure to consider in evaluating the Company’s performance. Management uses Adjusted EBITDA, which it defines as earnings before interest, taxes, depreciation and amortization, impairment, one-time expenses, restructuring and share-based compensation expenses.

Although Adjusted EBITDA is not a measure of performance or liquidity calculated in accordance with IFRS, we believe the non-IFRS financial measures we present provide meaningful supplemental information regarding our operating results primarily because they exclude certain non-cash charges or items that we do not believe are reflective of our ongoing operating results when budgeting, planning and forecasting and determining compensation, and when assessing the performance of our business with our senior management. However, investors should not consider these measures in isolation or as substitutes for operating income, cash flows from operating activities or any other measure for determining the Company’s operating performance or liquidity that is calculated in accordance with IFRS. In addition, because Adjusted EBITDA is not calculated in accordance with IFRS, it may not necessarily be comparable to similarly titled measures employed by other companies. The non-IFRS measures included in this press release have been reconciled to the IFRS results in the tables below.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx^®, is an investigational therapy for the debridement of chronic wounds, with potential to become a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

Cautionary Note Regarding Forward-Looking Statements

MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.

Specifically, this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates, including EscharEx^® and NexoBrid^®. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; our contracts with governmental agencies; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future.

These and other significant factors are discussed in greater detail in MediWound’s annual report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 5, 2026 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound’s current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law.

MediWound Contacts:
Hani Luxenburg Chief Financial Officer MediWound Ltd. ir@mediwound.com		Daniel Ferry Managing Director LifeSci Advisors, LLC daniel@lifesciadvisors.com

MediWound,Ltd. Condensed Consolidated Statements of Financial Position U.S. dollars in thousands
		Dec 31,
		2025		2024
CURRENT ASSETS:
Cash and cash equivalents and short-term bank deposits		53,140		43,161
Trade and other receivable, net		2,731		6,310
Inventories		4,093		2,692
Total current assets		59,964		52,163
NON-CURRENT ASSETS:
Other receivables and long-term restricted bank deposit		467		439
Property, plant and equipment		18,640		14,132
Right of use assets		7,151		6,663
Intangible assets		33		99
Total non-current assets		26,291		21,333
Total assets		86,255		73,496
CURRENT LIABILITIES:
Current maturities of long-term liabilities		870		612
Warrant		12,659		17,092
Trade payables and accrued expenses		7,648		5,281
Other payables		4,531		3,556
Total current liabilities		25,708		26,541
NON-CURRENT LIABILITIES:
Grants received in advance		-		736
Liabilities in respect of IIA grants		8,291		8,149
Lease liabilities		8,152		6,513
Severance pay liability, net		472		404
Total non-current liabilities		16,915		15,802
Total liabilities		42,623		42,343
Shareholders' equity*		43,632		31,153
Total liabilities & equity		86,255		73,496

^{*Shareholders' equity: Issued and Outstanding Ordinary shares of NIS 0.07 par value: 12,835,185 as of December 31, 2025 and 10,793,057 as of December 31, 2024} 

MediWound, Ltd. Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss U.S. dollars in thousands (except of share and per share data)
		Twelve months ended						Three months ended
		Dec 31,						Dec 31,
		2025			2024			2025			2024
Total Revenues		16,959			20,222			1,867			5,840
Cost of revenues		13,705			17,588			1,589			4,937
Gross profit		3,254			2,634			278			903
Research and development		14,320			8,878			4,478			2,986
Selling and Marketing		5,765			4,936			1,380			1,470
General and administrative		8,448			8,202			2,237			2,530
Other (Income) expenses		(13	)		18			(17	)		18
Operating loss		(25,266	)		19,400)	)		(7,800	)		(6,101	)
Finance income (expenses), net		1,556			(10,763	)		690			2,211
Taxes on income		(169	)		(61	)		(73	)		(18	)
Net loss		(23,879	)		(30,224	)		(7,183	)		(3,908	)
Foreign currency translation adjustments		(21	)		7			(2	)		4
Total comprehensive loss		(23,900	)		(30,217	)		(7,185	)		(3,904	)
Basic and diluted net loss per share		(2.10	)		(3.03	)		(0.56	)		(0.36	)
Number of shares used in calculating basic and diluted loss per share		11,376,571			9,959,723			12,825,516			10,790,959

MediWound,Ltd. Condensed Consolidated Statements of Cash Flows U.S. dollars in thousands
	Twelve months ended						Three months ended
	Dec 31,						Dec 31,
	2025			2024			2025			2024
	Audited						Unaudited
Cash Flows from Operating Activities:
Net Loss	(23,879	)		(30,224	)		(7,183	)		(3,908	)
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to profit and loss items:
Depreciation and amortization	1,860			1,483			690			397
Share-based compensation	3,108			3,138			662			822
Revaluation of warrants accounted at fair value	(2,158	)		10,704			(320	)		(1,964	)
Revaluation of liabilities in respect of IIA grants	380			752			(324	)		41
Revaluation of liabilities in respect of TEVA	-			770			-			-
Financing income and exchange differences of lease liability	1,725			487			439			249
Increase (decrease) in severance liability, net	31			(30	)		(21	)		16
Other income	(13	)		18			(17	)		18
Financial income, net	(1,891	)		(2,039	)		(550	)		(553	)
Unrealized foreign currency loss (gain)	(51	)		47			(17	)		(27	)
	2,991			15,330			542			(1,001	)
Changes in assets and liability items:
Decrease (increase) in trade receivables	3,211			(1,141	)		2,753			(1,426	)
Decrease (increase) in inventories	(1,363	)		187			350			348
Decrease in other receivables	1,665			120			1,904			403
Increase (decrease) in trade payables and accrued expenses	2,350			406			(59	)		2,354
Increase in grants received in advance	-			1,181			-			1,181
Increase (decrease) in other payables	(1,096	)		517			(1,323	)		412
	4,767			1,270			3,625			3,272
Net cash used in operating activities	(16,121	)		(13,624	)		(3,016	)		(1,637	)

MediWound, Ltd. Condensed Consolidated Statements of Cash Flows U.S. dollars in thousands
Cash Flows from Investing Activities:
Purchase of property and equipment	(5,505	)		(6,273	)		(2,452	)		(806	)
Interest received	1,591			2,252			182			664
Proceeds from (Investment in) short term bank deposits, net	(14,036	)		(4,376	)		(21,621	)		4,970
Net cash provided by (used in) investing activities	(17,950	)		(8,397	)		(23,891	)		4,828
Cash Flows from Financing Activities:
Repayment of lease liabilities	(1,212	)		(928	)		(345	)		(242	)
Proceeds from exercise of warrants and share options	3,630			1,210			6			-
Proceeds from issuance of shares	27,416			22,165			(753	)		(271	)
Repayments of IIA grants	(214	)		(219	)		-			-
Repayment of liabilities in respect of TEVA	-			(2,834	)		-			-
Net cash provided by (used in) financing activities	29,620			19,394			(1,092	)		(513	)
Exchange rate differences on cash and cash equivalent balances	95			(84	)		61			2
Increase (decrease) in cash and cash equivalents	(4,356	)		(2,711	)		(27,938	)		2,680
Balance of cash and cash equivalents at the beginning of the period	9,155			11,866			32,737			6,475
Balance of cash and cash equivalents at the end of the period	4,799			9,155			4,799			9,155

MediWound, Ltd. Adjusted EBITDA U.S. dollars in thousands
		Twelve months ended						Three months ended
		Dec 31,						Dec 31,
		2025			2024			2025			2024
Net loss		(23,879	)		(30,224	)		(7,183	)		(3,908	)
Adjustments:
Financial income (expenses), net		1,556			(10,763	)		690			2,211
Other income (expenses), net		13			(18	)		17			(18	)
Taxes on income		(169	)		(61	)		(73	)		(18	)
Depreciation and amortization		(1,860	)		(1,483	)		(690	)		(397	)
Share-based compensation expenses		(3,108	)		(3,138	)		(662	)		(822	)
Total adjustments		(3,568	)		(15,463	)		(718	)		956
Adjusted EBITDA		(20,311	)		(14,761	)		(6,465	)		(4,864	)

FAQ

What did MediWound (MDWD) report for full-year 2025 revenue and cash on March 5, 2026?

Full-year 2025 revenue was $17.0 million and cash, cash equivalents and deposits were $53.6 million. According to the company, revenue declined from $20.2M in 2024, while cash strengthened following a $30.0M registered direct offering.

How is the EscharEx Phase III VALUE trial progressing for MDWD and what are the key timing expectations?

The EscharEx Phase III VALUE trial is advancing as planned with enrollment ongoing across ~40 sites targeting 216 patients. According to the company, a pre-specified interim sample size assessment and enrollment completion are expected by year-end 2026.

What is the status of MediWound's NexoBrid manufacturing capacity and regulatory timing for MDWD?

The expanded NexoBrid manufacturing facility is operational and increases capacity sixfold to support global demand. According to the company, commercial supply from the facility remains subject to regulatory approvals expected in 2026.

What revenue guidance did MediWound (MDWD) reaffirm for 2026–2028 on March 5, 2026?

MediWound reaffirmed guidance of $24–26M for 2026, $32–35M for 2027, and $50–55M for 2028. According to the company, guidance assumes continued support from BARDA and the U.S. Department of War.

Why did MediWound (MDWD) report lower revenue in 2025 compared to 2024?

Revenue decreased primarily due to lower development services revenue and reduced product sales to Vericel, partly attributable to a U.S. government shutdown that delayed budget approvals. According to the company, these factors lowered 2025 revenue versus 2024.

How did MediWound's profitability and expenses change in 2025 versus 2024 for MDWD?

Operating loss increased to $25.3M in 2025 and R&D rose to $14.3M, driven by the EscharEx Phase III trial. According to the company, net loss narrowed to $23.9M from $30.2M due to favorable non-cash warrant revaluation.